Diabetes, Metabolic Syndrome and Cardiovascular Disease

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Buy your copy of this report @ http://www.reportsnreports.com/reports/75197-diabetes-metabolic-syndrome-and-cardiovascular-disease.html

Report Details:

Published: July 2012

No. of Pages: 237

Price: Single User License – US$3400             Corporate User License – US$6800

                                                   

Table of Contents
1. Overview 9
1.1 Statement of Report 9
1.2 About This Report 9
1.3 Scope of the Report 10
1.4 Methodology 10
1.5 Executive Summary 12
2. Introduction 15
2.1 Demographics of Diabetes 16
2.1.1 Worldwide Diabetes 16
2.1.2 U.S. Diabetes 18
2.2 Economics of Diabetes 21
3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 26
3.1 Pre-Diabetes Syndrome 27
3.2 Metabolic Syndrome 27
3.3 Diabetes and Inflammation 32
3.4 Diagnosis of Diabetes Mellitus 33
3.5 Progression of Diabetes 33
3.6 Risk Factors and Diabetes 34
3.6.1 Obesity 35
3.6.2 Stress-Induced Hyperglycemia 37
3.7 Complications and Co-Morbidities in Type 2 Diabetes 37
3.7.1 Preventing Complications and Co-Morbidities in Diabetes 40
3.8 Hypoglycemia Resulting From Treatment 42
3.9 Cardiovascular Disease (CVD) 42
3.9.1 CVD Facts 42
3.9.2 Cardiac Care Therapeutics 49
3.9.2.1 Anti-Hypertensive Drugs 51
3.9.2.2 Cholesterol Management Drugs 51
3.9.2.3 Anticoagulants 55
3.9.3 CVD Diagnostics 55
4. Pharmaceutical Industry and the Anti-Diabetes Market 58
4.1 The Worldwide Pharmaceutical Industry 58
4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure 58
4.1.2 Global Pharmaceutical Market 60
4.2 Total Diabetes Drug Market Size and Growth 65
4.2.1 Sales of Anti-Diabetic Drugs Continue to Rise 68
4.3 Diabetic Medications Overview 69
4.3.1 Recent Trends in Diabetic Drug Usage 70
4.3.2 Market Influence Factors 74
5. Non-Insulin Anti-Diabetes Products 76
5.1 Anti-Diabetic Drug Therapy Overview 76
5.1.1 Sulfonylureas 80
5.1.2 Meglitinides 81
5.1.3 Biguanides 82
5.1.4 Thiazolidinediones (TZDs) 83
5.1.5 ?-Glucosidase Inhibitors 86
5.1.6 Incretin Mimetics/Glucagon-Like Peptide (GLP-1) Analogs and Agonists 87
5.1.6.1 Byetta (Exenatide) 88
5.1.6.2 Victoza (Liraglutide) 88
5.1.6.3 Bydureon (exenatide LAR) 88
5.1.7 Amylin Analog 89
5.1.8 DPP-IV Inhibitors 89
5.1.8.1 Januvia (Sitagliptin) 89
5.1.8.2 Onglyza (Saxagliptin) 90
5.1.8.3 Tradjenta (Linagliptin) 90
5.1.9 Combination Therapy 90
5.1.9.1 Youth With Recent-Onset Type 2 Diabetes Should Be Started on Combination Therapies 92
5.1.10 Comparisons of the Anti-Diabetes Drugs 92
5.2 Drivers and Trends 92
5.2.1 Market Share of Anti-Diabetic Drugs 92
5.2.2 Forecasts for Anti-Diabetic Drugs 93
5.2.3 Sales Forecast for the Global Diabetes Market 94
5.3 The Future 95
5.3.1 Practice Patterns 95
5.3.2 New Products in Pipeline 96
5.3.2.1 Novel GLP-1 Agonists and Analogs 96
5.3.2.2 Novel DPP-IV Inhibitors 98
5.3.2.3 Sodium Glucose Cotransporter 2 (SGLT-2) 98
5.3.2.4 Emerging Non-Insulin Anti-Diabetes Targets and Drugs in the Pipeline 99
5.3.2.5 Novel Approaches to Finding New Drug Targets 103
5.4 Anti-Diabetic Drug Patent Expiry 103
5.5 Regulatory Issues 103
6. Insulin 104
6.1 Insulin Markets 104
6.1.1 Major Players and Market Share 106
6.1.2 Patent Expirations 107
6.1.3 Innovation Strategies 108
6.2 Insulin Therapeutics 108
6.2.1 Recommendations for Insulin Initiation and Administration 109
6.2.2 Short-Acting Insulin 111
6.2.3 Rapid-Acting Insulin 111
6.2.4 Intermediate-Acting Insulin 113
6.2.5 Long-Acting Insulin 113
6.2.6 Long-Acting Insulins in Development 115
6.2.7 Insulin Mixtures 115
6.3 Pipeline Insulin 116
6.4 Non-Invasive Insulin Delivery 116
6.4.1 Inhaled Insulin 117
6.4.1.1 A Chronicle of Inhaled Insulins 118
6.4.2 Oral Insulin 120
6.4.3 Transdermal Insulin 124
6.5 Barriers for Non-Injected Insulin 126
6.6 Patient Potential for Non-Injected Insulin 126
6.7 Insulin Delivery Devices 126
6.7.1 Insulin Pens 127
6.7.2 Injections Aids 132
6.7.2.1 Automatic Injectors 133
6.7.2.2 Syringe Magnifiers 134
6.7.2.3 Injection Ports 134
6.7.3 Insulin Jet Injectors 134
6.7.4 Insulin Pumps 135
6.7.4.1 External Insulin Pumps 136
6.7.4.2 Insulin Patch Pumps in Development 141
6.7.4.3 Implantable Insulin Pumps 143
6.7.4.4 Insulin Pump Market Share 145
6.7.4.5 Drivers of Demand for Pumps 146
6.8 Market Forecasts for Insulin Administration Technologies 146
7. Emerging Anti-Diabetes Technologies and Products 148
7.1 Projections for the Anti-Diabetes Drug Market 148
7.2 Artificial Pancreas 151
7.3 Insulin-Producing Cells 152
7.3.1 Cell Therapy Companies for Diabetes 153
7.4 Transplantation Procedures 155
7.4.1 Pancreatic Transplantation 156
7.4.1.1 Pancreatic Organ Transplantation 156
7.4.1.2 Allo-Islet Transplantation 156
7.4.1.3 Transplantation of Encapsulated Pancreatic Cells 156
7.4.1.4 Implantation of Genetically Engineered ?-Cells or Embryonic Stem Cells 156
7.4.2 Current Status 157
7.5 Gastric Bypass Surgery to Treat Type 2 Diabetes 158
7.6 Immune Modulators 158
7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes 159
7.8 Other Anti-Diabetic Therapy Drug Candidates 159
7.8.1 Lipid Abnormalities 160
7.8.2 High Blood Pressure 161
7.8.3 Anticoagulants 162
7.9 Drugs Used “Off-Label” 163
7.9.1 Warfarin Sodium 163
8. Diagnosing Diabetes Using In Vitro Laboratory Tests 164
8.1 New Diagnostic Guidelines 164
8.2 Diabetes Tests 165
8.2.1 Fasting Plasma Glucose (FPG) Test 165
8.2.2 Glucose Tolerance Test 166
8.2.3 Test for Glycosylated Hemoglobin 167
8.2.4 Fructosamine 168
8.3 Glucose Monitoring 169
8.3.1 Overview of Market Segment 171
8.3.2 Competitive Strategies 171
8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix 173
8.3.3.1 First-Generation Monitors 174
8.3.3.2 Second-Generation Monitors 174
8.3.3.3 Third-Generation SMBG Technologies 174
8.3.3.4 Product Overview 174
8.3.4 What Are the Advantages of Using a Continuous Glucose-Monitoring Device? 182
8.3.5 Minimally-Invasive Continuous Glucose Monitors in Development 184
8.3.6 Future of Non-Invasive Glucose Technology 184
8.3.7 Lancets and Lancing Devices 184

For more details Contact:   sales@reportsandreports.com

Retailing in India

The Indian retail market has grown at a double-digit compound annual growth rate over the last five years and was worth an estimated $554bn in 2011. The Indian economy grew throughout the global downturn, with increasing consumer purchasing power bolstering the retail sector. Retailing is now the second highest contributor to India’s gross domestic product.
Features and benefits

• Uncover the main opportunities available in the Indian retail market across Clothing, Grocery, Electricals, Health and Beauty and Homewares
• Understand the size of the Indian market by sector and the growth forecasts to 2015
• Understand the key financial, cultural, political and logistical reasons that has so far held back the development of modern retail in India
• Discover which retailers are operating in India and with which local partners

Highlights
Confusion reigns over India's FDI policy. Currently international food and grocery retailers are prohibited from entering the Indian market, except through cash and carry wholesale trading, but the government announced plans to lift restrictions in 2011, but then committed an embarrassing u-turn just weeks later.
The emergence of modern retail started in the major cities of Delhi, Mumbai, and Bangalore, and the satellite towns which have developed around them due to the huge influx of young professionals. Modern retail is concentrated in just a few cities, and premium locations there have already become saturated.
Employing 8% of the total work force, retail is the second largest employer in the country. The majority of these workers are self-employed, as India has a huge base of traditional retail outlets which are often family-owned. At present, modern retail represents only 5–7% of total retail in India.
Your key questions answered

• Why has India's organised retail sector taken so long to develop, and what is continuing to hold it back?
• How large is the retail opportunity in India, and which sectors are most amenable to entry by foreign retailers?
• Which international players are operating in India and who do they partner with?

Buy your copy of this report @ http://www.reportsnreports.com/reports/182415-retailing-in-india.html

Report Details:

Published: July 2012

No. of Pages: 136

Price: Single User License – US$4495             Corporate User License – US$11238

                                                   

Clinical Laboratory Testing Volume 1: IVD Reagents and Instruments Markets

Clinical laboratory in vitro diagnostic (IVD) testing for reagent and instrument sales is one of the most important sectors of medical care. By all accounts, it is a very mature, large market employing over 100,000 laboratory workers and spawning an industry for reagents and instruments comprised of thousands of companies worldwide. The term clinical laboratory testing usually refers to determining the concentration or activity of a protein, carbohydrate, lipid, electrolyte, enzyme or small molecule in easily collected body fluids such as blood, serum, plasma or urine. However, it is not necessarily limited to these determinations. The purpose of this TriMark Publications report is to describe the specific segments of the global clinical laboratory instrumentation and reagent market. Within this area, the report covers segments that are highly active in terms of innovation and growth. Specifically, this clinical laboratory testing report examines the markets for small lab equipment all the way up to highly-automated, large lab platforms, as well as accessory equipment such as reagents, supplies and manufacturers' original equipment manufacturer (OEM) additional equipment. The emphasis is on companies and products that are actively developing and marketing laboratory analyzer products for the clinical setting, including hospitals, independent labs, physician's offices and miscellaneous clinics. This study concentrates on the clinical laboratory instrumentation industry market segment and the companion reagents sector in the U.S. and around the world. The regional markets and their differences are examined, including in Europe, Asia (Japan, China and India) and the rest of the world (ROW).

Buy your copy of this report @ http://www.reportsnreports.com/reports/181583-clinical-laboratory-testing-volume-1-ivd-reagents-and-instruments-markets.html

Report Details:

Published: July 2012

No. of Pages: 279

Price: Single User License – US$3400             Corporate User License – US$6800

Table of Contents

1. Overview 8
1.1 Objectives of the Report 8
1.2 Methodology 9
1.3 Scope of the Report 10
1.4 Executive Summary 11

2. IVD Industry 19
2.1 Industry Overview 19
2.2 IVD Industry Leading Players Comparison and Review 19
2.2.1 Roche Diagnostics 20
2.2.2 Abbott Laboratories 22
2.2.3 Siemens Healthcare Diagnostics 25
2.2.4 Becton, Dickinson & Co. 26
2.2.5 Beckman Coulter, Inc. 26
2.2.6 Ortho-Clinical Diagnostics 31
2.2.7 bioMérieux 32
2.2.8 Sysmex 32
2.2.9 Bio-Rad Laboratories, Inc. 32
2.2.10 ARKRAY, Inc. 33
2.2.11 Cytyc Corporation (A Hologic Company) 33
2.2.12 Gen-Probe, Inc. 33
2.3 Biotechnology Reagents and Supplies 34
2.3.1 Vendor Quality Assurance 36
2.3.2 Partnership Support 36
2.3.3 Protecting Supply of Raw Materials 37
2.3.4 Selecting a Second Source for Chemicals 38
2.3.5 Cost Analysis for Reagent Manufacture 39
2.3.6 Outsourcing Production of Reagents 39
2.4 The Fastest Growing IVD Reagent Markets 39
2.5 High Growth Applications Spur Industry Growth 40
2.6 Automated Instrument Platforms Evolution 41
2.7 Reagents and Supplies Market for Clinical Lab Instruments 41
2.8 Spending for Clinical Laboratory Testing 41
2.8.1 Reimbursement Pressure 42
2.8.2 Medicare Part B Spending Trends 43
2.8.3 Strategies for Revenue Growth 45
2.8.4 Electronic Health Records 45

3. IVD Clinical Laboratory Instrument and Reagent Market 46
3.1 Markets 46
3.1.1 Global Markets 46
3.1.2 Global Drivers of Clinical Laboratory Testing 48
3.1.3 Global Outlook 49
3.1.4 U.S. Market 50
3.1.5 European IVD Instruments and Reagents Market 54
3.1.5.1 German Clinical Laboratory Diagnostic Markets 63
3.1.5.2 U.K. Clinical Laboratory Testing Diagnostic Product Market 65
3.1.5.2.1 U.K. Competitive Analysis 65
3.1.5.2.2 U.K. Market Access 67
3.1.5.3 French Clinical Laboratory Diagnostic Testing Products Market 67
3.1.5.4 Italian Clinical Laboratory Diagnostic Products Market 68
3.1.5.5 Spanish Clinical Laboratory Diagnostic Market 69
3.1.5.6 Finnish Clinical Laboratory Products Market 70
3.1.5.7 Turkish Clinical Laboratory Products Market 71
3.1.5.8 Belgium Clinical Laboratory Diagnostic Products Market 72
3.1.5.9 Swiss Clinical Laboratory Diagnostic Products Market 72
3.1.5.10 Dutch Clinical Laboratory Diagnostic Products Market 73
3.1.5.11 Portuguese Clinical Laboratory Diagnostic Products Market 73
3.1.5.12 Austrian Clinical Laboratory Diagnostic Products Market 74
3.1.5.13 Greek Clinical Laboratory Diagnostic Products Market 75
3.1.5.14 Polish Clinical Laboratory Diagnostic Products Market 75
3.1.5.15 Romanian Clinical Laboratory Diagnostic Products Market 76
3.1.5.16 Czech Republic Clinical Laboratory Diagnostic Products Market 77
3.1.5.17 Swedish Clinical Laboratory Diagnostic Products Market 77
3.1.5.18 Norwegian Clinical Laboratory Diagnostic Products Market 78
3.1.5.19 Irish Clinical Laboratory Diagnostic Products Market 78
3.1.5.20 Hungarian Clinical Laboratory Diagnostic Products Market 79
3.1.5.21 Bulgarian Clinical Laboratory Diagnostic Products Market 79
3.1.5.22 Slovakian Clinical Laboratory Diagnostic Products Market 80
3.1.5.23 Lithuanian Clinical Laboratory Diagnostic Products Market 81
3.1.5.24 Latvian Clinical Laboratory Diagnostic Products Market 81
3.1.5.25 Estonian Clinical Laboratory Diagnostic Products Market 82
3.1.5.26 Slovenian Clinical Laboratory Products Diagnostic Market 82
3.1.5.27 Russian Clinical Laboratory Diagnostic Products Market 83
3.1.6 Asian Markets 83
3.1.6.1 Indian Clinical Laboratory Diagnostic Products Market 85
3.1.6.1.1 Indian IVD Testing Instrument and Reagents Industry 85
3.1.6.2 Japanese Clinical Laboratory Testing Products Market 91
3.1.6.3 Chinese Clinical Laboratory Instrument and Reagent Market 92
3.1.7 Clinical Laboratory Smaller Country Markets 103
3.1.7.1 Canadian Clinical Laboratory Market 103
3.1.7.2 Brazilian Clinical Laboratory Instrument and Reagent Market 103
3.1.7.3 Australian Clinical Laboratory Instrument and Reagent Market 105
3.1.8 ROW Clinical Laboratory Testing Instrument and Reagent Market 105
3.1.9 Overview of Asian Clinical Laboratory Instrument and Reagent Market 106
3.1.9.1 Singapore 107
3.1.9.2 Malaysia 109
3.1.9.3 Thailand 109
3.1.9.4 Indonesia 110
3.1.9.5 Philippines 110
3.1.9.6 South Korea 110
3.1.9.7 India 111
3.1.9.8 Hong Kong 111
3.1.9.9 Taiwan 111
3.1.10 Overview of the Latin American Diagnostics Market 112
3.2 Clinical Laboratory Sector 113
3.2.1 Key Industry Players 113
3.2.2 Market Specialization 116
3.2.3 Revenue and Reimbursement 118
3.2.4 Companies 119
3.3 Outlook for Clinical Laboratory Testing 120
3.3.1 Long-term Changes 120
3.3.2 Market Drivers 121
3.3.3 The Limits to Growth 123
3.3.4 Hot Sectors in the IVD Market 123
3.3.5 Key Technologies 125
3.3.6 Conclusion 125

Browse reports related to Healthcare @ http://www.reportsnreports.com/market-research/healthcare/

Bacterial Partnering Terms and Agreements

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual bacterial deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of bacterial dealmaking and business activities.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in bacterial dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading bacterial deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bacterial deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all bacterial deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all bacterial partnering deals signed and announced since 2007. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all bacterial partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bacterial partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bacterial technologies and products.

Buy your copy of this report @ http://www.reportsnreports.com/reports/175339-bacterial-partnering-terms-and-agreements.html

Report Details:

Published: July 2012

No. of Pages: 801

Price: Single User License – US$1995             Corporate User License – US$2995

Major points covered in Table of Contents of this report include:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in bacterial dealmaking

Chapter 3 – Leading bacterial deals

Chapter 4 – Bigpharma bacterial deals  

Chapter 5 – Bacterial partnering contracts directory

Chapter 6 – Bacterial dealmaking by indication 

Chapter 7 – Partnering resource center

Table of Figures

Browse reports related to Boitechnology @ http://www.reportsnreports.com/market-research/biotechnology/

2012 – 2017 Personal & Professional Service Robotics Market

The service robotics market report forecasts and assesses the professional and personal service robotics by applications, and geography from 2012 to 2017. The report analyses the service robotics application market, both qualitatively and quantitatively, giving in-depth insights about each sub segment of all application as well. Industrial service robots can be used to carry out simple tasks, such as examining welding, as well as more complex, harsh-environment tasks, such as aiding in the dismantling of nuclear powers stations. Autonomous scientific robots perform tasks which humans would find difficult or impossible, from the deep sea to outer space. The Woods Hole Sentry can descend to 4,500 meters and allows a higher payload as it does not need a support ship or the oxygen and other facilities demanded by human piloted vessels.

The service robotics market research report aims to capture the market roadmap with market sizes, revenue forecasts, value chain, competitive landscape, leading players and their key developments, strategies, and profiles. Market is split into five regions; namely Americas, Europe, Japan, APAC, and ROW for the geographic analysis of the market.

The global service robotics market in 2011 was worth $18.39 billion. This market is valued at $20.73 billion in 2012 and expected to reach $46.18 billion by 2017 at an estimated CAGR of 17.4% from 2012 to 2017. The market is driven by factors like ageing population, value enhancement by robots, increasing grants and funds by governments, increasing venture capital investments in service robotics companies, enhancements in complementary technologies and integration of robotics with mobile technologies, other smart products, and appliances.

The key market players in service robotics industry are Honda Motors (Japan), iRobot (U.S.), AB Electrolux (Sweden), Sony (Japan), Fujitsu (Japan), Toyota (Japan), GeckoSystems (U.S.), and Yujin Robot (South Korea).

Scope of the report

The service robotics market research report categorizes the global market on the basis of them being used in various applications, and geographical analysis; forecasting revenue, and analyzing trends in the market.

The global service robotics market is segmented into:

• This report highlights the basic structure of the service robotics market; i.e. professional and personal service robotics by applications and geography. The report covers the major applications such as defense, rescue & security; agriculture & forestry; aerospace; infrastructure; medical; underwater; others for the professional service robotics. Domestic, entertainment, security, education are covered under personal service robotics.
• The report sizes all the sub markets by geography by giving detailed geographic split into Americas, Europe, Japan, APAC, and Rest of the World (ROW).

Buy your copy of this report @ http://www.reportsnreports.com/reports/175337-personal-professional-service-robotics-market-global-forecast-assessment-by-applications-geography-2012-2017-.html

Report Details:

Published: July 2012

No. of Pages: 208

Price: Single User License – US$4650              Corporate User License – US$7150

Major points covered in Table of Contents of this report include:

1 INTRODUCTION 
2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW

4 APPLICATIONS MARKET

5 GEOGRAPHIC ANALYSIS

6 COMPETITIVE LANDSCAPE

7 COMPANY PROFILES

List of Tables

List of Figures

Asia-Pacific Data Center Services Market 2010

Datacenter services includes colocation and managed hosting services. The research study covers the Asia Pacific datacenter services market, examining drivers and restraints for growth, exploring trends that are impacting the market and the key market participants in each of the countries being covered. Forecasts and market sizing are included in this study with the base year is 2010 with forecasts running through 2017. For each market, emerging trends have been identified.

Buy your copy of this report @ http://www.reportsnreports.com/reports/174275-asia-pacific-datacenter-services-market-2010.html

Report Details:

Published: June 2012

No. of Pages: 258

Price: US$7500             

Major points covered in Table of Contents of this report include:

• Executive Summary
• Market Overview
• Australian Datacenter Services Market 2010
• Chinese Datacenter Services Market 2010
• Hong Kong Datacenter Services Market 2010
• Indian Datacenter Services Market 2010
• Indonesian Datacenter Services Market 2010
• Malaysian Datacenter Services Market 2010
• New Zealand Datacenter Services Market 2010
• The Philippines Datacenter Services Market 2010
• Singapore Datacenter Services Market 2010
• South Korean Datacenter Services Market 2010
• Taiwanese Datacenter Services Market 2010
• Thailand Datacenter Services Market 2010
• Vietnamese Datacenter Services Market 2010
• The Last Word (Conclusions and Implications)

Browse reports related to IT & Telecommunication @ http://www.reportsnreports.com/market-research/information-technology/

The Mexico Defense Industry Market Opportunities and Entry Strategies, Analyses and Forecasts to 2016

Mexican defense expenditure, valued at US$5.5 billion in 2011, registered a CAGR of 8.7% during the review period and is expected to grow at a CAGR of 10.2% during the forecast period (2012-2016), to reach an estimated US$8.97 billion in 2016. Furthermore, Mexico’s cumulative defense expenditure over the forecast period is expected to be US$37.7 billion, of which US$36.1 billion is expected to be revenue expenditure (see graph below for reference).  

Corruption is rampant in the Mexican armed forces, specifically in the army. There is increasing evidence of the expanding role of the Mexican military in the drug war and it is suspected that arms procured by the army are passed to the drug cartels, which use the arms to enhance their drug trade. There is also concern that US aid to Mexico — US$1.4 billion has been pledged to help Mexico reduce drug trafficking — could be used for criminal activity or for personal gain by top military officials. Moreover, there is a lack of transparency in defense contracts awarded to international suppliers, with the government classifying most defense procurements as top secret. Overall, corruption and a lack of transparency are hindering the growth of Mexico’s defense industry.

Buy your copy of this report @ http://www.marketreportsonline.com/172261-the-mexican-defen.html

Report Details:

Published:  June 2012
No. of Pages: 113

Price: Single User License – US$1250              Corporate User License – US$3750

  

As the Mexican defense industry comprises of only state-owned companies with little specialization in weapon categories. The resulting lack of advanced defense technology means that foreign weapons suppliers who intend to conduct business in Mexico face infrastructure challenges. Although foreign suppliers can bring advanced technology to Mexico, this results in technology imports without offset incentives, as the defense offset terms are not clearly defined by the Mexican MoD. Consequently, foreign suppliers find pursuing a defense opportunity in Mexico challenging.

Offset obligation provides an opportunity for the development of domestic infrastructural and technological capabilities. However, Mexico has not disclosed any offset obligations imposed for its arms procurement, which is partially responsible for the lack of development in the domestic defense industry. In March 2009, its first major offset agreement was signed between Mexico and France in which, with the purchase of six EC 725 multipurpose helicopters worth US$300 million from Eurocopter, the French company set up an assembly facility in Mexico worth US$500 million, which will help Mexico develop its aeronautical capabilities. However, during the forecast period, the country is also expected to give preference to arms exporters who provide technology transfers to offset equipment imports.